Pioneered mRNA vaccine technology with its COVID-19 shot Spikevax, now developing mRNA vaccines and therapies for flu, RSV and cancer.
Pioneered mRNA vaccine technology with its COVID-19 shot Spikevax, now developing mRNA vaccines and therapies for flu, RSV and cancer.
Has one commercial franchise: COVID shots, sold first under government supply contracts and now in the US mainly through pharmacies and health providers on a seasonal vaccination cycle, so sales swing with take-up. Its newer RSV shot is small by comparison. The company has cut spending to stretch cash while its pipeline matures.
Moat: narrow (IP / patents, process know-how). A pioneering mRNA platform and manufacturing know-how, though platform advantages face growing competition.
Headquarters: Cambridge, Massachusetts, US · Founded: 2010 · Employees: 4,700
Size Moderna (MRNA) is a United States Health Care company (Biotechnology) with a market value of $79.6B, the 170th largest of 3,085 United States companies the cockpit tracks. Shares closed at $196.79 on 18 Nov 2026.
Performance Over six months the shares gained 309.0%, against +33.9% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 14 in its peer set.
Growth Revenue grew 13.1% over the last twelve months (peer median +8.6%); the operating margin is -116.0% (peer median 30.7%).
Valuation It trades at 31.2× enterprise value to sales against a peer median of 7.3× (most expensive of 14).
Capital Return on invested capital runs 49.9 points below its cost of capital (10.6% WACC).
Credit Moderna has 1 bond outstanding ($3.00B).
Short interest Short interest is 8.2% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.52B | $1.94B | $3.24B | $6.84B | $19.1B |
| Revenue growth | — | -40% | -53% | -64% | — |
| Gross profit | $450M | $861M | $1.58B | $1.53B | $13.3B |
| EBITDA | -$2.67B | -$2.86B | -$3.76B | -$3.63B | $9.61B |
| Net income | -$2.79B | -$2.82B | -$3.56B | -$4.71B | $8.36B |
| Free cash flow | -$1.97B | -$2.06B | -$4.05B | -$3.83B | $4.58B |
| Capital expenditure | $259M | $202M | $1.05B | $707M | $400M |
| Total debt | $4.23B | $1.30B | $747M | $1.24B | $1.20B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Moderna MRNA | $79.6B | +309% | +13% | -116% | 31.2× | n/a |
| BioNTech SE Sponsored ADR BNTX | $20.6B | -8% | -21% | -61% | 1.9× | n/a |
| Novavax NVAX | $1.31B | -14% | -61% | -17% | 2.4× | n/a |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 2.6× | -4.8% |
| GSK GSK.L | $97.9B | -3% | +4% | 25% | 2.8× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MRNA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.7% | +1.6% | 2nd lowest of 14 |
| 6-month return | +309.0% | +33.9% | highest of 14 |
| Distance from 52-week high | -29.9% | -11.4% | 4th lowest of 14 |
| Revenue growth (TTM) | +13.1% | +8.6% | 6th highest of 14 |
| Operating margin | -116.0% | 30.7% | lowest of 14 |
| EV / Sales | 31.2× | 7.3× | most expensive of 14 |
| ROIC minus cost of capital | -49.9 pp | +3.9 pp | lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Moderna MRNA | United States | $79.6B | +309% | +13% | -116% | 31.2× | n/a | n/a |
| CSL CSL.AX | Australia | $63.7B | +102% | -2% | 26% | 4.8× | 6.8% | +11.0% |
| argenx SE Sponsored ADR ARGX | United States | $59.1B | +17% | +71% | 29% | 10.3× | 11.7% | +151.4% |
| Lonza LONN.SW | Switzerland | $53.9B | +36% | -11% | 25% | 7.8× | 15.6% | +7.7% |
| Samsung Biologics 207940.KS | South Korea | $48.7B | -6% | -20% | 43% | 14.5× | 7.0% | +31.4% |
| Iqvia IQV | United States | $42.5B | +50% | +9% | 14% | 3.3× | 16.8% | +7.5% |
| Natera NTRA | United States | $42.0B | +41% | +37% | -9% | 14.1× | n/a | n/a |
| Celltrion 068270.KS | South Korea | $34.9B | +12% | +40% | 32% | 9.0× | 10.6% | +17.6% |
| Genmab A/S GMAB.CO | Denmark | $30.8B | +103% | +15% | 31% | 8.4× | 11.6% | +19.5% |
| Gilead Sciences GILD | United States | $210B | +30% | +7% | 38% | 7.3× | -2.4% | +3.6% |
| Amgen AMGN | United States | $240B | +34% | +9% | 36% | 7.2× | 1.6% | +7.8% |
| United Therapeutics UTHR | United States | $24.6B | +2% | +2% | 44% | 7.1× | 0.3% | +16.5% |
| Wuxi Bio 2269.HK | Hong Kong | $23.1B | +35% | +22% | 32% | 6.7× | 20.8% | +30.2% |
| BioNTech SE Sponsored ADR BNTX | United States | $20.6B | -8% | -21% | -61% | 1.9× | n/a | n/a |
Moderna has 1 bond outstanding with $3.00B face value.